Nkarta (NKTX) Cash & Equivalents (2019 - 2026)
Nkarta (NKTX) posted quarterly Cash & Equivalents of $27.4 million for Q1 2026, down 47.99% year-over-year from $52.6 million in Q1 2025, and down 30.98% quarter-over-quarter from $39.6 million in Q4 2025.
Nkarta (NKTX) Cash & Equivalents (2019 - 2026) Analysis & Trends
Nkarta's Cash & Equivalents history runs 8 years deep, the most recent figure standing at $27.4 million for Q1 2026.
- In Q1 2026, Cash & Equivalents fell 47.99% year-over-year to $27.4 million; the TTM figure through Mar 2026 stood at $27.4 million (down 47.99% YoY), while the FY2025 annual figure was $39.6 million, up 42.19% from the prior year.
- Cash & Equivalents for Q1 2026 stood at $27.4 million, down from $39.6 million in the prior quarter.
- The five-year high for Cash & Equivalents was $250.3 million in Q1 2024, with the low at $27.4 million in Q1 2026.
- The 5-year median for Cash & Equivalents is $41.6 million (2022), against an average of $64.2 million.
- The sharpest annual moves came in 2022 and 2025: Cash & Equivalents soared 439.07% in 2022, then slumped 78.98% in 2025.
- Nkarta's Cash & Equivalents stood at $37.5 million in 2022, then decreased by 17.21% to $31.0 million in 2023, then declined by 10.2% to $27.9 million in 2024, then soared by 42.19% to $39.6 million in 2025, then slumped by 30.98% to $27.4 million in 2026.
- Business Quant data shows NKTX's Cash & Equivalents at $27.4 million in Q1 2026, $39.6 million in Q4 2025, and $60.1 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Equiv. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 6.14 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 2.46 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 3.58 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 1.72 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 5.10 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 1.71 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 8.93 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 544.80 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 811.99 Mn |
| 10 | Nkarta | 201.14 Mn | 201.14 Mn | - | 243.20 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 243.20 Mn |
| Mar 31, 2026 | 27.36 Mn |
| Dec 31, 2025 | 39.63 Mn |
| Sep 30, 2025 | 60.11 Mn |
| Jun 30, 2025 | 53.41 Mn |
| Mar 31, 2025 | 52.60 Mn |
| Dec 31, 2024 | 27.87 Mn |
| Sep 30, 2024 | 56.96 Mn |
| Jun 30, 2024 | 120.40 Mn |
| Mar 31, 2024 | 250.29 Mn |
| Dec 31, 2023 | 31.04 Mn |
| Sep 30, 2023 | 38.26 Mn |
| Jun 30, 2023 | 29.12 Mn |
| Mar 31, 2023 | 53.67 Mn |
| Dec 31, 2022 | 37.49 Mn |
| Sep 30, 2022 | 39.65 Mn |
| Jun 30, 2022 | 131.65 Mn |
| Mar 31, 2022 | 41.61 Mn |
| Dec 31, 2021 | 60.82 Mn |
| Sep 30, 2021 | 96.22 Mn |